TY - JOUR
T1 - Non-alcoholic fatty liver disease and 30-day all-cause mortality in adult patients with community-acquired pneumonia
AU - Nseir, W. B.
AU - Mograbi, J. M.
AU - Amara, A. E.
AU - Abu Elheja, O. H.
AU - Mahamid, M. N.
N1 - Publisher Copyright:
© The Author(s) 2018. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved.
PY - 2019/2/1
Y1 - 2019/2/1
N2 - Background: Non-alcoholic fatty liver disease (NAFLD) is a common and serious form of chronic liver disease. Risk factors of NAFLD include obesity and type 2 diabetes which are associated with infections. Aim: We aimed to determine the association of NAFLD with 30-day all-cause mortality in adult patients with communityacquired pneumonia (CAP). Methods: A retrospective cohort study on hospitalized patients with CAP that was conducted during a period of 4 years. We included patients aged 18 years with CAP who underwent abdominal ultrasonography. We compared between patients with and without NAFLD in term of age, gender, body mass index (BMI), comorbidities, CURB-65, pneumonia severity index (PSI), liver enzymes, C-reactive protein (CRP) and 30-day all-cause mortality. We used fibrosis score to distinguish between patients with NAFLD who have advanced fibrosis (F3-F4) and do not have (F0-F2). Results: A total of 561 patients were included in this study. The overall prevalence of NAFLD was 200/561 (35.6%). Significant differences were found between the groups with and without NAFLD in term of BMI, CURB-65, ALT, GGT and CRP. The 30- day all-cause mortality rate was 9.8% (55/561). Among the NAFLD group 34/200 (17%) subjects died vs. 21/361 (5.82%) among patients without NAFLD, P<0.001. Multi-variate logistic regression analysis after adjusting for other multiple covariates showed that NAFLD with fibrosis score 02 [odds ratio (OR) 1.38, 95% confidence interval (CI) 1.121.51, P0.04], NAFLD with fibrosis score> 2 (1.52; 1.251.70, P0.03) were associated with 30-day all-cause mortality among patients with CAP. Conclusions: NAFLD was associated with 30-day all-cause mortality in patients with CAP. This association was more significant in patients with advanced hepatic fibrosis.
AB - Background: Non-alcoholic fatty liver disease (NAFLD) is a common and serious form of chronic liver disease. Risk factors of NAFLD include obesity and type 2 diabetes which are associated with infections. Aim: We aimed to determine the association of NAFLD with 30-day all-cause mortality in adult patients with communityacquired pneumonia (CAP). Methods: A retrospective cohort study on hospitalized patients with CAP that was conducted during a period of 4 years. We included patients aged 18 years with CAP who underwent abdominal ultrasonography. We compared between patients with and without NAFLD in term of age, gender, body mass index (BMI), comorbidities, CURB-65, pneumonia severity index (PSI), liver enzymes, C-reactive protein (CRP) and 30-day all-cause mortality. We used fibrosis score to distinguish between patients with NAFLD who have advanced fibrosis (F3-F4) and do not have (F0-F2). Results: A total of 561 patients were included in this study. The overall prevalence of NAFLD was 200/561 (35.6%). Significant differences were found between the groups with and without NAFLD in term of BMI, CURB-65, ALT, GGT and CRP. The 30- day all-cause mortality rate was 9.8% (55/561). Among the NAFLD group 34/200 (17%) subjects died vs. 21/361 (5.82%) among patients without NAFLD, P<0.001. Multi-variate logistic regression analysis after adjusting for other multiple covariates showed that NAFLD with fibrosis score 02 [odds ratio (OR) 1.38, 95% confidence interval (CI) 1.121.51, P0.04], NAFLD with fibrosis score> 2 (1.52; 1.251.70, P0.03) were associated with 30-day all-cause mortality among patients with CAP. Conclusions: NAFLD was associated with 30-day all-cause mortality in patients with CAP. This association was more significant in patients with advanced hepatic fibrosis.
UR - http://www.scopus.com/inward/record.url?scp=85060831384&partnerID=8YFLogxK
U2 - 10.1093/qjmed/hcy227
DO - 10.1093/qjmed/hcy227
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 30325458
AN - SCOPUS:85060831384
SN - 1460-2725
VL - 112
SP - 95
EP - 99
JO - QJM: An International Journal of Medicine
JF - QJM: An International Journal of Medicine
IS - 2
ER -